查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585630

生物同质激素市场：按产品类型、荷尔蒙类型、最终用户划分 - 全球预测 2025-2030

Bioidentical Hormones Market by Product (Creams & Gels, Injectable, Patches & Implants), Hormones Type (Estrogens, Progesterone, Testosterone), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生物同质激素市场价值为4.9345亿美元，预计到2024年将达到6.1646亿美元，复合年增长率为25.02%，预计到2030年将达到23.5601亿美元。

生物同质激素被定义为分子结构与人体自然产生的荷尔蒙相似的人工激素，在治疗更年期、甲状腺疾病和荷尔蒙失衡等疾病方面具有显着的用途。其主要最终用途包括诊所、医院和私人药房的治疗应用。市场成长受到人们对天然和客製化荷尔蒙补充疗法日益增长的认识和需求的影响。随着世界老化，对生物同质激素的需求不断增加，以对抗与老龄化相关的荷尔蒙下降。此外，复合药局的技术进步正在实现个人化解决方案，进一步推动市场扩张。扩大宣传宣传活动，教育消费者了解生物同质激素的功效和安全性是一个潜在的机会。此外，与医疗保健提供者建立策略联盟和合作可以显着提高市场渗透率。由于都市化和医疗保健机会的增加，亚洲和拉丁美洲的新兴市场提供了充足的成长机会。

主要市场统计
基准年[2023] 4.9345亿美元
预测年份 [2024] 61646万美元
预测年份 [2030] 23.5601亿美元
复合年增长率（%） 25.02%

然而，市场面临重大限制和挑战，例如缺乏监管和标准化临床测试，这可能会影响公众认知并阻碍成长。此外，替代治疗方法的可用性以及卫生相关人员对其有效性的怀疑可能会阻碍其采用。业务成长的创新领域包括研究生物同质激素的新输送系统以及开发综合性患者教育平台以消除误解并加强信任。生物同质激素与其他药物的相互作用还有进一步研究的空间，这可能为更安全、更有效的联合治疗打开大门。

生物同质激素市场的特征是其动态性，受到持续的科学研究和医学趋势的推动。投资研究和开发稳定情绪或增强认知功能的生物同质配方的公司可能会占据重要的市场占有率。对于寻求在不断变化的市场格局中建立主导地位的公司来说，透明的传播策略和对基于证据的效益的关注至关重要。

市场动态：揭示快速发展的生物同质激素市场的关键市场洞察

供需的动态交互作用正在改变生物同质激素市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 增加荷尔蒙缺乏症筛检
    • 人群中荷尔蒙缺乏症的盛行率
    • 老年人口增加
  • 市场限制因素
    • 各种副作用，包括视力模糊以及乳癌和心臟病的风险
  • 市场机会
    • 已开发国家主要研究公司集中
    • 为特定患者客製化荷尔蒙疗法配方
  • 市场问题
    • 与合成荷尔蒙产品相比，产品纯度和安全性方面的品管不足

波特的五力：驾驭生物同质荷尔蒙市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解生物同质荷尔蒙市场的外部影响

外部宏观环境因素在塑造生物同质荷尔蒙市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解生物同质荷尔蒙市场的竞争格局

对生物同质激素市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生物同质荷尔蒙市场供应商的绩效评估

FPNV定位矩阵是评估生物同质荷尔蒙市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製生物同质荷尔蒙市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生物同质激素市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 增加荷尔蒙缺乏检测
      • 人群中荷尔蒙缺乏症的盛行率
      • 老年人口增加
    • 抑制因素
      • 它有多种副作用，包括视力丧失以及乳癌和心臟病的风险。
    • 机会
      • 已开发国家主要研究公司集中
      • 为特定患者客製化荷尔蒙疗法配方
    • 任务
      • 与合成荷尔蒙产品相比，产品纯度和安全性方面的品管不足
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章生物同质荷尔蒙市场：副产品

  • 介绍
  • 霜和凝胶
  • 注射
  • 贴片和植入
  • 锭剂和胶囊

第七章生物同质激素市场：依激素类型

  • 介绍
  • 雌激素
  • 黄体酮
  • 睪固酮

第八章生物同质激素市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 医院/诊所

第九章美洲生物同质荷尔蒙市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太生物同质荷尔蒙市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲生物同质荷尔蒙市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Bayers AG
  • BIoTe Medical, LLC
  • Defy Medical, LLC
  • Full Life Wellness Center
  • Merck KGaA
  • NextGenRx Compounding Pharmacy
  • Novartis AG
  • Noven Pharmaceuticals, Inc. Hisamitsu Group
  • Novo Nordisk A/S
  • Nueva Aesthetics
  • Optimal Health and Wellness
  • Pavilion Compounding Pharmacy, LLC
  • Pellecome, LLC
  • Pfizer Inc.
  • Schwietermans Pharmacy
  • The Biostation
  • TherapeuticsMD, Inc.
Product Code: MRR-431C35F6C1E4

The Bioidentical Hormones Market was valued at USD 493.45 million in 2023, expected to reach USD 616.46 million in 2024, and is projected to grow at a CAGR of 25.02%, to USD 2,356.01 million by 2030.

Bioidentical hormones, defined as man-made hormones similar to the ones naturally produced by the human body in molecular structure, have notable necessity and applications in treating conditions like menopause, thyroid disorders, and hormonal imbalances. Their primary end-use scopes span across therapeutic applications in clinics, hospitals, and individual pharmacies. The market's growth is influenced by increasing awareness and demand for natural and tailored hormone replacement therapies. With an aging global population, there is a heightened demand for bioidentical hormones to address age-related hormone declines. Additionally, technological advancements in compounding pharmacies allow for personalized solutions, further fueling market expansion. Potential opportunities lie in expanding awareness campaigns to educate consumers on bioidentical hormone efficacy and safety. Furthermore, forming strategic alliances and collaborations with healthcare providers can significantly enhance market penetration. Emerging markets in Asia and Latin America present ample growth opportunities, driven by increasing urbanization and healthcare access.

KEY MARKET STATISTICS
Base Year [2023] USD 493.45 million
Estimated Year [2024] USD 616.46 million
Forecast Year [2030] USD 2,356.01 million
CAGR (%) 25.02%

However, the market faces significant limitations and challenges, including regulatory scrutiny and a lack of standardized clinical trials, which can affect public perception and hinder growth. Moreover, the availability of alternative treatments and skepticism among medical professionals regarding efficacy can pose barriers to widespread adoption. Innovative areas for business growth include research into novel delivery systems for bioidentical hormones and the development of comprehensive patient education platforms to dispel misconceptions and reinforce trust. There is also room for further research into bioidentical hormone interactions with other medications, which could open doors to safer and more effective combination therapies.

The bioidentical hormone market is characterized by its dynamic nature, driven by continuous scientific research and healthcare trends. Companies investing in R&D for enhanced bioidentical formulations capable of stabilizing mood or boosting cognitive functions could capture significant market share. Focusing on transparent communication strategies and evidence-based benefits will be crucial for businesses seeking to establish a leadership position in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bioidentical Hormones Market

The Bioidentical Hormones Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing screening for hormonal deficiency
    • Prevalence of hormonal deficiency in the population
    • Rise in geriatric population
  • Market Restraints
    • Varying side effects such as blurred vision or risk of breast cancer and heart attack
  • Market Opportunities
    • Concentration of major research companies in the developed countries
    • Formulation of customized hormonal therapy for specific patients
  • Market Challenges
    • Lack of quality control on purity and safety of the product compared to synthetic hormone products

Porter's Five Forces: A Strategic Tool for Navigating the Bioidentical Hormones Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bioidentical Hormones Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bioidentical Hormones Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bioidentical Hormones Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bioidentical Hormones Market

A detailed market share analysis in the Bioidentical Hormones Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bioidentical Hormones Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bioidentical Hormones Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bioidentical Hormones Market

A strategic analysis of the Bioidentical Hormones Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioidentical Hormones Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayers AG, Biote Medical, LLC, Defy Medical, LLC, Full Life Wellness Center, Merck KGaA, NextGenRx Compounding Pharmacy, Novartis AG, Noven Pharmaceuticals, Inc. Hisamitsu Group, Novo Nordisk A/S, Nueva Aesthetics, Optimal Health and Wellness, Pavilion Compounding Pharmacy, LLC, Pellecome, LLC, Pfizer Inc., Schwietermans Pharmacy, The Biostation, and TherapeuticsMD, Inc..

Market Segmentation & Coverage

This research report categorizes the Bioidentical Hormones Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Creams & Gels, Injectable, Patches & Implants, and Tablets & Capsules.
  • Based on Hormones Type, market is studied across Estrogens, Progesterone, and Testosterone.
  • Based on End User, market is studied across Academic & Research Institutes and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing screening for hormonal deficiency
      • 5.1.1.2. Prevalence of hormonal deficiency in the population
      • 5.1.1.3. Rise in geriatric population
    • 5.1.2. Restraints
      • 5.1.2.1. Varying side effects such as blurred vision or risk of breast cancer and heart attack
    • 5.1.3. Opportunities
      • 5.1.3.1. Concentration of major research companies in the developed countries
      • 5.1.3.2. Formulation of customized hormonal therapy for specific patients
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of quality control on purity and safety of the product compared to synthetic hormone products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bioidentical Hormones Market, by Product

  • 6.1. Introduction
  • 6.2. Creams & Gels
  • 6.3. Injectable
  • 6.4. Patches & Implants
  • 6.5. Tablets & Capsules

7. Bioidentical Hormones Market, by Hormones Type

  • 7.1. Introduction
  • 7.2. Estrogens
  • 7.3. Progesterone
  • 7.4. Testosterone

8. Bioidentical Hormones Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Hospitals & Clinics

9. Americas Bioidentical Hormones Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bioidentical Hormones Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bioidentical Hormones Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bayers AG
  • 3. Biote Medical, LLC
  • 4. Defy Medical, LLC
  • 5. Full Life Wellness Center
  • 6. Merck KGaA
  • 7. NextGenRx Compounding Pharmacy
  • 8. Novartis AG
  • 9. Noven Pharmaceuticals, Inc. Hisamitsu Group
  • 10. Novo Nordisk A/S
  • 11. Nueva Aesthetics
  • 12. Optimal Health and Wellness
  • 13. Pavilion Compounding Pharmacy, LLC
  • 14. Pellecome, LLC
  • 15. Pfizer Inc.
  • 16. Schwietermans Pharmacy
  • 17. The Biostation
  • 18. TherapeuticsMD, Inc.

LIST OF FIGURES

  • FIGURE 1. BIOIDENTICAL HORMONES MARKET RESEARCH PROCESS
  • FIGURE 2. BIOIDENTICAL HORMONES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOIDENTICAL HORMONES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOIDENTICAL HORMONES MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PATCHES & IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PROGESTERONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TESTOSTERONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, 2023